Tuesday , April 20 2021

[바이오 유망기업]Líder Utrex's leading global reserve company for next generation immunocarcinogen

[이데일리 이미나 기자]
[이데일리 김지섭 기자] "Innovative drug-based immunotherapeutic technologies will develop cell therapies and antibody therapies, and will become global leaders in the field of immunosuppressive drugs through rapid commercialization."

Kwon Byung-se, the dealer's representative, met with reporters at the Hotel Plaza in Jung-gu, Seoul on the 16th.

Utrex is a biotechnology company that develops drugs for intractable diseases, such as cancer, by immunotherapy, using the "immune system," which protects viruses and toxins in the human body. The mission statement, "Utrex", also showed the intention to develop new immunotherapeutic drugs, such as & # 39; US & # 39; (new), & # 39; TI & # 39; (immunotherapy) and & # 39; LEX & # 39; (method).

The immunotoxic treats cancer cells with a normal immune system or strengthens the weakened immune system in several ways to remove cancer cells. In comparison to conventional anticancer drugs or target cancer drugs that target specific cancer cells, they are less drug resistant and safe from side effects such as leukopenia and hair loss. According to GBI Research, the market for immunotherapy drugs is expected to grow at an average annual rate of 23.9 percent from 18 trillion won in 2015 to 86 trillion won in 2022.

◇ Immunology research & # 39; Hanwoo & # 39; … Original technology acquired for immunotherapy

Kwon Byung-seh, who founded Utilities in February 2015, is an authority in the field of immunology, who has been working on selling kangwoo products. He was a professor of chemistry and bioscience at the University of Ulsan and head of the Immunocytochemistry Division of the National Cancer Center at Yale University. Kwon said: "The study of immunology in the last 40 years has led to the development of differentiated immunotherapy."

In particular, he was first noticed in 1989 when he discovered the "4-1BB" receptor, which stimulates immune modulator-related "T cells". T cells, an immune cell, attack and destroy cancer cells. 4-1BB can selectively activate or reduce immune function to activate T cells. Utrex is using this to separate and culture T cells from the blood of cancer patients and then inject them into the patient's body.

(EBViNT Cell), which treats lymphoma, laryngeal cancer, stomach cancer, etc., is a monophasic glioblastoma / malignant tumor that treats non-small cell lung cancer and breast cancer in ½ stage. WTiNT Cell, which treats glioma, etc., is in phase one. "Aptity Cell will complete its second phase of clinical trials by 2020," he said. "It aims to be licensed by the US Food and Drug Administration (FDA) in 2022 through the designation of innovative medicines."

In addition, a T-cell treatment expressing the chimeric antigen receptor (CAR-T) which enhances the anti-cancer effect by introducing a gene that successfully discovers and successfully destroys T-cell (CAR) cancer cells. The CAR therapeutic agent -T existing has caused side effects, such as cytokine syndrome, which indiscriminately attacks normal cells and causes hypotension and acute kidney damage. However, CAR-T Therapeutics of Utilities reduced the adverse effects by targeting only the malignant cells, targeting HDL-DR, an antigen expressed when normal cells were transformed into malignant cells. By standardizing the production process and standardizing the product, the cost of the drug, which reached several hundred million won, was reduced considerably. Other drugs, such as EU101 and EU102, which are active in the treatment of cancer cells activating the immune response of T cells, are being developed.

These new development drugs are also actively seeking technology exports. Kwon said: "There are many technologies we have now, but it is impossible to develop them all." He said, "We will raise clinical costs through technology exports and collaborate with global pharmaceutical companies to build success stories."

◇ New drug development in the US, such as the bridgehead … Aspiration & Global Big Pharma & # 39;

Kwon's main priority is to establish a bridgehead in the US and Europe for the development of new medicines. In September, we signed a Memorandum of Understanding (MOU) with JGB Business Link International and ABB Anti-Cell to successfully enter US. JGBLI will support research and development (R & D) centers in the United States and consultations with the Maryland College of Pharmacy for the approval of anticancer drugs. "This is the first step in clinical trials for T-cell therapy in the United States," Kwon said. "We will continue to make efforts to license immunocompromised medications, starting with the VientiCell App."

The KOSDAQ list for clinical funding is also ahead. On December 15, he passed the preliminary screening of the Korea Stock Exchange and confirmed the planned amount of 27.6 billion won to 36.4 billion won. He said: "The purpose of listing is to make management transparent and contribute to the growth of the company," he said. "From the year 2022 until the year of launching products and technology exports, etc. Growth until 2013, the" Let's achieve our vision. "

Source link